- Mechanism
- Neutralizes myostatin and activin A
- Typical research dose
- 10-100 mcg/kg in animal models
- Route
- subcutaneous
- Half-life
- Unknown (extended local tissue binding)
- Legal status
- Research Only
Overview
Follistatin (344/315) is a synthetic glycoprotein originally identified for its role in inhibiting follicle-stimulating hormone. In modern research, the Follistatin (344/315) peptide is primarily recognized as a powerful myostatin inhibitor that binds to and neutralizes transforming growth factor-beta (TGF-β) superfamily members. By blocking these catabolic pathways, it significantly promotes muscle hypertrophy and hyperplasia. This makes it a critical subject of study for treating muscle-wasting disorders and exploring advanced performance enhancement.
Potential Benefits
- Muscle Hypertrophy: By neutralizing myostatin, the Follistatin (344/315) peptide removes natural limits on muscle growth, leading to significant increases in mass (Datta-Mannan A et al., 2013).
- Enhanced Physical Strength: The profound increase in muscle fiber size and density directly correlates with improved contractile force in animal models.
- Prevention of Muscle Wasting: Research indicates its potential to combat cachexia and sarcopenia by blocking catabolic signaling pathways mediated by activin A and myostatin.
- Tissue Repair and Healing: Its interaction with TGF-β pathways suggests a role in cellular regulation, potentially aiding recovery from musculoskeletal injuries (Fitzgerald AM et al., 2012).
- Fat Loss Support: Secondary to massive increases in metabolically active muscle tissue, subjects often exhibit improved body composition and reduced adiposity.
Side Effects
Common side effects:
- Injection site irritation and redness
- Mild joint pain during initial growth phases
- Temporary water retention
- Increased appetite and lethargy
Rare or serious side effects:
- Unregulated tissue growth
- Potential cardiovascular strain due to rapid mass gain
- Alterations in reproductive hormones including FSH suppression
- Ligament and tendon strain from disproportionate muscle strength
Follistatin (344/315) is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Myostatin and Activin A Neutralization forms the primary mechanism of action for the Follistatin (344/315) peptide. It functions as a binding protein that attaches directly to myostatin (GDF-8) and activin A, preventing them from binding to their cellular receptors. Because myostatin normally acts as a negative regulator of skeletal muscle growth, its neutralization removes the biological brakes on muscle development.
Isoform Specificity dictates the distinct pharmacokinetic properties of Follistatin 344 and 315. Follistatin 344 is a precursor that cleaves into the tissue-bound Follistatin 315 isoform, which exhibits a strong affinity for heparan sulfate proteoglycans on cell surfaces (Datta-Mannan A et al., 2013). This localized binding ensures that the peptide exerts its potent anabolic effects directly within skeletal muscle tissue while minimizing systemic circulation.
Origin & History
Initial Discovery of follistatin occurred in the late 1980s when researchers isolated it from porcine follicular fluid, identifying it as a novel polypeptide that inhibits the release of follicle-stimulating hormone (Esch FS et al., 1987). Subsequent genetic sequencing, including the isolation of bovine follistatin cDNA, revealed its broader role as a regulatory glycoprotein across multiple species (Saleh M et al., 1994).
Regulatory Status remains strictly confined to laboratory and preclinical settings, as the FDA has not approved Follistatin (344/315) for human therapeutic use. Due to its potent muscle-building properties, it has gained attention in performance-enhancing circles, prompting the development of specific assays to detect black market follistatin 344 in anti-doping efforts (Reichel C et al., 2019). Currently, it is legally available only as a research-only compound for in vitro and animal studies.